Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
CTX-471 trial terminated after combo arm misses efficacy; two device trials await startOct 9Weekly roundup, 3 itemsCompass TherapeuticsCTX-471
Compass Therapeutics awaits FDA input on tovecimig biliary cancer dataAug 6Quarterly updateCompass Therapeutics
Compass Therapeutics registers Phase 2 study of CTX-471 in NCAM-positive neuroendocrine tumorsJul 6Trial updateCompass TherapeuticsCTX-471